Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: Results from SYNERGY

International Journal of Cardiology

Volumn 144, Issue 1, 2010, Pages 36-41

  Spinler, Sarah A ^a,b   Mahaffey, Kenneth W ^c   Gallup, Dianne ^c   Levine, Glenn N ^d   Ferguson III, James J ^e   Rao, Sunil V ^c   Gallo, Richard ^f   Ducas, John ^g   Goodman, Shaun G ^h   Antman, Elliott ⁱ   White, Harvey D ^j   Biasucci, Luigi ^k   Becker, Richard C ^c   Col, Jacques J ^l   Cohen, Marc ^m   Harrington, Robert A ^c   Califf, Robert M ^c  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e MEDICINES COMPANY   (United States)

^f MONTREAL HEART INSTITUTE   (Canada)

^g UNIVERSITY OF MANITOBA   (Canada)

^h ST MICHAEL'S HOSPITAL   (Canada)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j Green Lane Cardiovascular Service ^*  (New Zealand)

^k CATHOLIC UNIVERSITY   (Italy)

^l CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^m NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

more..

Author keywords

Acute coronary syndromes; Bleeding; Chronic kidney disease; Enoxaparin; Heparin; Renal insufficiency

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE MB; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; THIENOPYRIDINE DERIVATIVE; TIROFIBAN; TROPONIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CREATININE CLEARANCE; ELECTROCARDIOGRAPHY; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; CREATININE; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEART CATHETERIZATION; HUMANS; KIDNEY; MALE; MIDDLE AGED; PROGNOSIS; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 77957870413     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.03.119     Document Type: Article

References (17)

1. M.J. Sarnak, A.S. Levey, and A.C. Schoolwerth Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation 108 2003 2154 2189
2. C.M. Gibson, D.S. Pinto, and S.A. Murphy Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality J Am Coll Cardiol 42 2003 1535 1543
3. S.A. Spinler, S.M. Inverso, and M. Cohen Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies Am Heart J 146 2003 33 41
4. J.L. Januzzi, C.P. Cannon, and P.M. DiBattiste Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial) Am J Cardiol 90 2002 1246 1249
5. P.J. Best, R. Lennon, and H.H. Ting The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions J Am Coll Cardiol 39 2002 1113 1119
6. S.S. Naidu, F. Selzer, and A. Jacobs Renal insufficiency is an independent predictor of mortality after percutaneous coronary intervention Am J Cardiol 92 2003 1160 1164
7. D.P. Chew, A.M. Lincoff, and H. Gurm Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial) Am J Cardiol 95 2005 581 585
8. SYNERGY Executive Committee The SYNERGY trial: study design and rationale Am Heart J 143 2002 952 960
9. J.J. Ferguson, R.M. Califf, and E.M. Antman Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial JAMA 292 2004 45 54
10. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
11. S.V. Rao, K.W. Mahaffey, and K. Chiswell Baseline predictors of bleeding in patients treated for acute coronary syndromes with either enoxaparin or unfractionated heparin: results from the superior yield of the new strategy of enoxaparin, revascularization and glycoprotein IIb/IIIa inhibitors (SYNERGY) Trial J Am Coll Cardiol 45 Suppl A 2005 247A Abstract 850-5
12. G.W. Stone, B.T. McLaurin, and D.A. Cox Bivalirudin for patients with acute coronary syndrome N Engl J Med 355 2006 2203 2216
13. K.A. Fox, and S.R. Mehta Impact of renal function on the benefit-risk ratio of fondaparinux in patients with non-ST elevation acute coronary syndromes in the OASIS-5 trial Paper presented at: XXI International Society on Thrombosis and Haemostasis Congress; July 6-12 2007; Geneva, Switzerland 2007 Abstract P-M-682
14. K.A.A. Fox, J.P. Bassand, and S.R. Mehta Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non-ST-segment elevation acute coronary syndromes Ann Intern Med 147 1997 304 310
15. R.C. Becker, F.A. Spencer, and M. Gibson Influence of patients characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes Am Heart J 143 2002 753 759
16. J.S. Hulot, G. Montalescot, P. Lechat, P. Collet, A. Ankri, and S. Urien Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome Clin Pharmacol Ther 77 2005 542 552
17. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150